Meng Yang1, Ke Zu2, Lorelei A Mucci3,4, Jennifer R Rider3,4, Michelangelo Fiorentino3,5, Steven K Clinton6, Massimo Loda7,8, Meir J Stampfer2,3,4, Edward Giovannucci2,3,4. 1. Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, 02115, USA. meyang@hsph.harvard.edu. 2. Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, 02115, USA. 3. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, 02115, USA. 4. Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA. 5. Pathology Unit, Addarii Institut, S.Orsola-Malpighi Hospital, 40138, Bologna, Italy. 6. The Division of Medical Oncology, The Department of Internal Medicine, The Ohio State University, Columbus, OH, 43210, USA. 7. Department of Pathology, Harvard Medical School, Boston, MA, 02115, USA. 8. Department of Pathology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
Abstract
BACKGROUND: Higher Gleason grade is associated with prostate cancer mortality; however, there is significant heterogeneity in this association. We evaluated whether vessel morphology, a biomarker of angiogenesis, aided in distinguishing mortality risks among men with high Gleason grading. METHODS: We characterized vessel morphology (area and irregularity) among 511 patients diagnosed with prostate cancer during 1986 to 2000, re-reviewed Gleason grade, and followed men through 2012. Men were grouped according to integrated vessel lumen irregularity and vessel area across Gleason grade. The more angiogenic group was identified as those with more irregular vessel lumen and smaller vessel area. Crude rates (95 % confidence intervals) and survival probability were estimated across Gleason grade and vessel morphology. RESULTS: During a median 14-year follow-up, 62 men developed bone metastases or died of prostate cancer. Lethality rates were uniformly low within Gleason grade categories 6 and 7(3 + 4), regardless of vessel morphology. However, among men with Gleason grades of 7(4 + 3) or 8-10, the more angiogenic group was associated with fourfold higher risk of lethal outcomes compared to those with less angiogenic potential. Ten-year survival probability ranged from 95 to 74 % according to the extent of vessel morphology (p < 0.0001, log-rank test). CONCLUSIONS: Vessel morphology may aid Gleason grading in predicting prostate cancer mortality risks among men diagnosed with high-grade Gleason cancers.
BACKGROUND: Higher Gleason grade is associated with prostate cancer mortality; however, there is significant heterogeneity in this association. We evaluated whether vessel morphology, a biomarker of angiogenesis, aided in distinguishing mortality risks among men with high Gleason grading. METHODS: We characterized vessel morphology (area and irregularity) among 511 patients diagnosed with prostate cancer during 1986 to 2000, re-reviewed Gleason grade, and followed men through 2012. Men were grouped according to integrated vessel lumen irregularity and vessel area across Gleason grade. The more angiogenic group was identified as those with more irregular vessel lumen and smaller vessel area. Crude rates (95 % confidence intervals) and survival probability were estimated across Gleason grade and vessel morphology. RESULTS: During a median 14-year follow-up, 62 men developed bone metastases or died of prostate cancer. Lethality rates were uniformly low within Gleason grade categories 6 and 7(3 + 4), regardless of vessel morphology. However, among men with Gleason grades of 7(4 + 3) or 8-10, the more angiogenic group was associated with fourfold higher risk of lethal outcomes compared to those with less angiogenic potential. Ten-year survival probability ranged from 95 to 74 % according to the extent of vessel morphology (p < 0.0001, log-rank test). CONCLUSIONS: Vessel morphology may aid Gleason grading in predicting prostate cancer mortality risks among men diagnosed with high-grade Gleason cancers.
Entities:
Keywords:
Angiogenesis; Gleason grade; Prostate cancer mortality; Vessel morphology
Authors: Ke Zu; Lorelei Mucci; Bernard A Rosner; Steven K Clinton; Massimo Loda; Meir J Stampfer; Edward Giovannucci Journal: J Natl Cancer Inst Date: 2014-01-24 Impact factor: 13.506
Authors: Ahmed Alhusban; Ahmad Al-Azayzih; Anna Goc; Fei Gao; Susan C Fagan; Payaningal R Somanath Journal: J Pharmacol Exp Ther Date: 2014-07-02 Impact factor: 4.030
Authors: Lorelei A Mucci; Anna Powolny; Edward Giovannucci; Zhiming Liao; Stacey A Kenfield; Rulong Shen; Meir J Stampfer; Steven K Clinton Journal: J Clin Oncol Date: 2009-10-26 Impact factor: 44.544
Authors: Jennifer R Stark; Sven Perner; Meir J Stampfer; Jennifer A Sinnott; Stephen Finn; Anna S Eisenstein; Jing Ma; Michelangelo Fiorentino; Tobias Kurth; Massimo Loda; Edward L Giovannucci; Mark A Rubin; Lorelei A Mucci Journal: J Clin Oncol Date: 2009-05-11 Impact factor: 44.544
Authors: Rebecca E Graff; Andreas Pettersson; Rosina T Lis; Thomas U Ahearn; Sarah C Markt; Kathryn M Wilson; Jennifer R Rider; Michelangelo Fiorentino; Stephen Finn; Stacey A Kenfield; Massimo Loda; Edward L Giovannucci; Bernard Rosner; Lorelei A Mucci Journal: Am J Clin Nutr Date: 2016-01-27 Impact factor: 7.045
Authors: Qiao-Li Wang; Mingyang Song; Steven K Clinton; Lorelei A Mucci; Jesper Lagergren; Edward L Giovannucci Journal: Eur J Epidemiol Date: 2022-01-13 Impact factor: 8.082
Authors: Verónica Torres-Estay; Michalis Mastri; Spencer Rosario; Patricia Fuenzalida; Carolina E Echeverría; Emilia Flores; Anica Watts; Javier Cerda-Infante; Viviana P Montecinos; Paula C Sotomayor; Julio Amigo; Carlos Escudero; Francisco Nualart; John M L Ebos; Dominic J Smiraglia; Alejandro S Godoy Journal: Cancers (Basel) Date: 2022-09-29 Impact factor: 6.575